Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine −

PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing

PharmaCielo Settles Debt Interest with Equity Amidst Liquidity Concerns

By The Northwire Desk — AI Analysis May 19, 2026 · 07:31 PCLO · 0.09 Pharmacielo Ltd.
Executive Summary
  • PharmaCielo Ltd. issued 11,145,999 common shares to satisfy $891,681.85 in semi-annual interest payments on its 11% secured debentures.
  • The effective price per share for this issuance was $0.08.
  • This transaction is a related party deal involving L5 Capital Inc., Marc Lustig, William Petron, and Ian Atacan.
  • An update on the insider bridge loan facility indicates $2.5 million of a $3.0 million commitment has been utilized since February 2024 to support working capital.
  • The issuance is subject to a 4-month statutory hold period under Canadian securities laws.
  • Regulatory compliance was maintained using exemptions under MI 61-101 as the fair market value does not exceed 25% of market capitalization.
Material Impact
  • The share issuance for debt interest confirms the company's inability to service debt obligations in cash, a known risk highlighted since December 2025.
  • Since the intention to issue these shares was announced on April 17, 2026, this May 19 announcement is execution of previously disclosed plans rather than new information.
  • The dilution from issuing ~11 million shares at $0.08 is negative for existing shareholders but priced in following the April intention release.
  • The bridge loan update reveals insiders have drawn down nearly all available committed capital ($2.5M of $3M), signaling limited internal liquidity buffers remain.
  • While routine relative to prior announcements, the underlying financial distress remains material given the looming principal maturity on June 30, 2026.
PCLO · Price
Company Overview
  • PharmaCielo operates in the cannabis and pharmaceutical sector, focusing on CBD/THC product lines and GACP-certified dried flower exports.
  • Key markets include Latin America, Brazil, South Africa, Australia, and the EU.
  • The company previously divested its La Margarita property to strengthen the balance sheet and repay a Banco Agrario loan.
  • Management has stated an aim for profitability in 2026 driven by cost structure improvements and export expansion.
Read the original news release →

More from Pharmacielo Ltd.

Apr 17, 2026 · 07:31

PharmaCielo Dilutes Shareholders to Service Debt as Principal Maturity Looms

Other Mar 17, 2026 · 07:31

PharmaCielo Announces the Issuance of Interest Shares

Financings Mar 02, 2026 · 07:31

PharmaCielo Announces 2025 Q3 Results, AGM Details

Earnings Feb 17, 2026 · 19:49

Pharmacielo schedules AGM, plans debt settlement

Financings Feb 17, 2026 · 07:46

PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

Financings Dec 30, 2025 · 12:53

Pharmacielo cease trade order revoked by OSC

Regulatory